ArticleBMC urology2022

Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysis.

Yifan Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.